Role of the PAR4 Thrombin Receptor in Stabilizing Platelet-platelet Aggregates as Revealed by a Patient with Hermansky-Pudlak Syndrome

Summary

Individuals with Hermansky-Pudlak Syndrome (HPS) lack platelet dense granules and have no ADP-autocrine response. Despite these platelet deficiencies, HPS patients exhibit a surprisingly mild bleeding phenotype. We hypothesize that activation of the PAR4 thrombin receptor compensates for the lack of an ADP-autocrine response by the P2Y12 ADP receptor in individuals with HPS. Here, we determine that PAR4 activation by thrombin occurs well after ADP release from dense granules in normal individuals. However, the signal from PAR4 stabilizes platelet-platelet aggregate formation in the absence of P2Y₁₂ activation by ADP. Thus, the strong signal emanating from PAR4 during platelet aggregation would provide an explanation for the mild bleeding diathesis of HPS.

Keywords

Hermansky-Pudlak Syndrome (HPS) - PAR4 - PAR1 - P2Y12

• References

• 1 Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Action. Cell 1991; 64: 1057-68.
• 2 Xu W-F, Andersen H, Whitmore TE, Presnell SR, Yee DP, Ching A, Gilbert T, Davie EW, Foster DC. Cloning and Characterization of Human Protease-Activated Receptor 4. Proc Natl Acad Sci (USA) 1998; 95: 6642-6.
• 3 Kahn ML, Zheng Y-W, Huang W, Bigornia V, Zheng D, Moff S, Farese RV, Tam C, Coughlin SR. A Dual Thrombin Receptor System for Platelet Activation. Nature 1998; 394: 690-4.
• 4 Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J, Costello CE. Plasmin Desensitization of the PAR1 Thrombin Receptor: Kinetics, Sites of Truncation, and Implications for Thrombolytic Therapy. Biochemistry 1999; 38: 4572-85.
• 5 Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000; 275: 6819-23.
• 6 Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74-8.
• 7 Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39: 5458-67.
• 8 Rao AK, Willis J, Holmsen H. A major role of ADP in thromboxane transfer experiments: studies in patients with platelet secretion defects. J Lab Clin Med 1984; 104: 116-26.
• 9 Moore SA, Steinhubl SR. Clopidogrel and Coronary Stenting: What is the Next Question?. J Thromb Thrombolysis 2000; 10: 121-6.
• 10 Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 15: 4156-65.
• 11 Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci (USA) 1998; 95: 8070-4.
• 12 Hermansky F, Pudlak P. Albanism Associated with Hemorrhagic Diathesis and Unusual Pigmented Reticular Cells in the Bone Marrow: Report of Two Cases with Histochemical Studies. Blood 1959; 14: 162-9.
• 13 King RA, Hearing VJ, Creel VJ, Oetting WS. in Metabolic and Molecular Bases of Inherited Disease. 8th edn. Vol. IV eds. Scriver CR, Beaudet AL, Sly WS, Valle DL. 5587-5627 McGraw-Hill; New York: 2001
• 14 Anikster Y, Huizing M, White J, Shevchenko YO, Fitzpatrick DL, Touchman JW, Compton JG, Bale SJ, Swank RT, Gahl WA, Toro JR. Mutation of a new gene causes a unique form of Hermansky-Pudlak syndrome in a genetic isolate of central Puerto Rico. Nat Genetics 2001; 28: 376-80.
• 15 Witkop CJ, Babcock MN, Rao GH. et al. Albinism and Hermansky-Pudlak syndrome in Puerto Rico. Bol Asoc Med PR 1990; 82: 333-9.
• 16 Huizing M, Gahl WG. Hermansky-Pudlak Syndrome and Chediak-Higashi Syndrome: Disorders of Vesicle Formation and Trafficking. Thromb Haemost 2001; 86: 233-45.
• 17 Ingal AH, Dixon J, Bailey A, Coombs ME, Cox D, McInally JI, Hunt SF, Kindon ND, Teobald BJ, Willis PA, Humphries RG, Leff P, Clegg JA, Smith JA, Tomlinson W. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem 1999; 42: 213-20.
• 18 Hsu-Lin S, Berman CL, Furie BC, August D, Furie B. A platelet membrane protein expressed during platelet activation and secretion. J Biol Chem 1984; 259: 9121-6.
• 19 Azam M, Andrabi SS, Sahr KE, Kamath L, Kuliopulos A, Chishti AH. Disruption of the mouse mu-calpain gene reveals an essential role in platelet function. Mol Cell Biol 2001; 21: 2213-20.
• 20 Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-Activated Receptors 1 and 4 Mediate Activation of Human Platelets by Thrombin. J Clin Invest 1999; 103: 879-87.
• 21 Rand MD, Lock JB, Veer CV, Gaffney DP, Mann KG. Blood Clotting in Minimally Altered Whole Blood. Blood 1996; 88: 3432-45.
• 22 Jacques SL, LeMasurier M, Sheridan PJ, Seeley SK, Kuliopulos A. Substrate-assisted catalysis of the PAR1 thrombin receptor. Enhancement of macromolecular association and cleavage. J Biol Chem 2000; 275: 40671-8.
• 23 Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980; 255: 154-61.
• 24 Muller B, Zerwes HG, Tangemann K, Peter J, Engel J. Two-step binding mechanism of fibrinogen to alpha IIb beta 3 integrin reconstituted into planar lipid bilayers. J Biol Chem 1993; 268: 6800-8.
• 25 Bazzoni G, Helmer ME. Are changes in integrin affinity and conformation overemphasized?. TIBS 1998; 23: 30-4.
• 26 Covic L, Kuliopulos A. unpublished data.